PITTSBURGH, Nov 24, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) today announced that the U.S. Food and Drug Administration has granted final approval for Mylan Technologies' Abbreviated New Drug Application for Fentanyl Transdermal System in 25 mcg/hr, 50 mcg/hr, 75 mcg/hr and 100 mcg/hr strengths. Fentanyl is the generic version of Alza Corporation's Duragesic^®, which had sales in excess of $1 billion for the 12-months ended June 30, 2003.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com.

SOURCE: Mylan Laboratories Inc.

For Mylan Laboratories Inc., Canonsburg
Kris King, 724-514-1800

Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.